Daruka Mahadevan, Joseph M. Unger, Catherine M. Spier, Daniel O. Persky, Fay Young, Michael LeBlanc, Richard I. Fisher and Thomas P. Miller Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma Cancer 119
Version of Record online: 25 JUL 2012 | DOI: 10.1002/cncr.27733
In this prospective cooperative group (Southwest Oncology Group) clinical trial, patients were investigated who had rare subtypes of newly diagnosed (approximately 80%) and relapsed/refractory (approximately 20%) peripheral T-cell non-Hodgkin lymphoma (PTCL), for which the standard of care is not established and outcomes are poor. The authors hypothesize that a combination of “non–P-glycoprotein substrate” agents—platinum, etoposide, gemcitabine, and methylprednisolone—will have greater efficacy in these patients than traditionally used cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like therapies.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field